References
- Ostermann ME, Keenan SP, Seiferling RA, Sibbald WJ. Sedation in the intensive care unit: A systematic review. JANIA 2000;283:1451–9.
- Mandema JW, Tuk B, Van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992;51:715–28.
- Bauer TM, Ritz R, Haberthur C, Ha HR, Hunkeler W, Sleight AJ, Scollo-Lavizarri G, Haefeli WE. Prolonged seda-tion due to accumulation of conjugated metabolites of midaazolam. Lancet 1995;346:145–7.
- MICROMEDEX® Healthcare Series. 3. Greenwood Village, Colorado: MICROMEDEX; 2000.
- Hawker F. Liver dysfunction in critical illness. Anaesth Intens Care 1991;19:165–81.
- Hals PA, Hall H, Dahl SG. Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug meta-bolites. Life Sci 1988;43: 405–12.
- Zimmerman HJ, Lewis JH. Drug-induced cholestasis. Med Toxicol 1987;2:112–60.
- Zimmerman HJ. Drug-induced liver disease. In Schiff ER, Sorrel MF, Maddrey WC, editors. Schiff's diseases of the liver, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 1999. pp 973–1064.
- Brown G, Scott W. Sedation in the intensive care unit. J Pharmac Hospital 1996;49:279.
- Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11: 272–6.
- Anonymous. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. hit J Chin Pharmacol Ther Toxicol 1990;28:317–22.
- Anonymous. Diagnostisch Kompas. In: Van Leusden Haim, editor. 2nd ed. Amstelveen: College voor Zorgverzekeringen; 1999. pp 493–802.
- Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs. II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J Chin Epidemiol 1993;46:1331–6.